Guidelines for Complications of Cancer Treatment Vol VIII Part B

parameters (gastric mucosal Pco2, skin capillary blood flowand red blood cell velocity, urine output) were measured.Increasing the MAP from 65 to 85 mm Hg with norepinephrineresulted in increases in cardiac index from 4.7+/-0.5 L/min/m2 to 5.5+/-0.6 L/min/m2 (p < 0.03). Arterial lactate was 3.1+/-0.9 mEq/L at a MAP of 65 mm Hg and 3.0+/-0.9 mEq/L at85 mm Hg (NS). The gradient between arterial P(CO2) andgastric intramucosal Pco2 was 13+/-3 mm Hg (1.7+/-0.4 kPa)at a MAP of 65 mm Hg and 16+/-3 at 85 mm Hg (2.1+/-0.4kPa) (NS). Urine output at 65 mm Hg was 49+/-18 mL/hr andwas 43+/-13 mL/hr at 85 mm Hg (NS). As the MAP was raised,there were no significant changes in skin capillary blood flowor red blood cell velocity. CONCLUSIONS: Increasing theMAP from 65 mm Hg to 85 mm Hg with norepinephrine doesnot significantly affect systemic oxygen metabolism, skinmicrocirculatory blood flow, urine output, or splanchnicperfusion.PMID: 10966242 [PubMed - indexed for MEDLINE]Bellomo R, Chapman M, Finfer S, et al. Low-dosedopamine in patients with early renal dysfunction: aplacebo-controlled randomised trial. Australian andNew Zealand Intensive Care Society (ANZICS) ClinicalTrials Group. Lancet. 2000; 356: 2139-43BACKGROUND: Low-dose dopamine is commonlyadministered to critically ill patients in the belief that it reducesthe risk of renal failure by increasing renal blood flow.However, these effects have not been established in a largerandomised controlled trial, and use of dopamine remainscontroversial. We have done a multicentre, randomised,double-blind, placebo-controlled study of low-dose dopaminein patients with at least two criteria for the systemicinflammatory response syndrome and clinical evidence of earlyrenal dysfunction (oliguria or increase in serum creatinineconcentration). METHODS: 328 patients admitted to 2393